Clinical Study of Collateral Puncture Treatment for Erythematotelangiectatic Rosacea

Phase 1

• Conditions: Rosacea

• Registration Number: ITMCTR2022000068
• Lead Sponsor: Guang'anmen Hospital,China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.It meets the diagnostic criteria for rosacea in the Chinese rosacea diagnosis and treatment guidelines (2021 Edition), and belongs to erythematotelangiectatic rosacea;
2.Age 18 to 70 years (including 18 and 70 years);
3.Sign the informed consent form

Exclusion Criteria

1.Patients with any systemic or active skin disease (such as connective tissue disease) that may affect the evaluation of experimental results on the face, or patients with scar, tattoo, birthmark or other pigmented skin disease on the affected part that may affect the evaluation of skin lesions;
2.Patients with serious primary diseases such as heart, cerebrovascular, liver, kidney or hematopoietic system, and patients with mental diseases or previous autoimmune diseases; Pregnant and lactating women; Photoallergic patients; Acupuncture syncope patients;
3.Within 30 days before treatment, oral immunomodulator (hydroxychloroquine sulfate tablets, etc.) ß Patients with rosacea related drugs such as adrenergic receptor inhibitors (carvedilol, etc.) and anti anxiety drugs (mirtazapine, paroxetine, etc.);
4.Patients who have used vasoconstrictors (0.5% bromonidine tartrate gel, 1% hydroxymethylzoline hydrochloride cream, etc.), calcineurin inhibitors, antibacterial agents and hormone ointment externally on the face within 7 days before treatment, and who have received fire acupuncture, bloodletting and LED light treatment on the face;
5.Patients who received facial injection, laser treatment and chemical exfoliation treatment within 30 days before treatment;
6.Patients who are participating in or have participated in other clinical trials within the last 3 months;
7.Patients who cannot tolerate any treatment in the test.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
clinician's telangiectasia assessment;clinician's erythema assessment;

Secondary Outcome Measures

Name	Time	Method
Dermatology Life Quality Index;rosacea quality of life index;investigator' s global assessment;patient' s self ? assessment;flushing assessment tool;